Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK.
Curr Opin Mol Ther. 1999 Jun;1(3):323-31. Review.
Similar articles
Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus.
Lewis EJ, Agrawal S, Bishop J, Chadwick J, Cristensen ND, Cuthill S, Dunford P, Field AK, Francis J, Gibson V, Greenham AK, Kelly F, Kilkushie R, Kreider JW, Mills JS, Mulqueen M, Roberts NA, Roberts P, Szymkowski DE.
Antiviral Res. 2000 Dec;48(3):187-96.
Human cytomegalovirus: challenges, opportunities and new drug development.
Antivir Chem Chemother. 1999 Sep;10(5):219-32. Review.
Viral targets for antisense oligonucleotides: a mini review.
Antiviral Res. 1998 Feb;37(2):67-81. Review. No abstract available.
Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs.
White DG, Maneewannakul K, von Hofe E, Zillman M, Eisenberg W, Field AK, Levy SB.
Antimicrob Agents Chemother. 1997 Dec;41(12):2699-704.
Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.
Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE.
Antiviral Res. 1997 Feb;33(3):201-13.
Antisense inhibition of virus infections.
Kilkuskie RE, Field AK.
Adv Pharmacol. 1997;40:437-83. Review. No abstract available.
Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication.
Diabata M, Enzinger EM, Monroe JE, Kilkuskie RE, Field AK, Mulder C.
Antiviral Res. 1996 Mar;29(2-3):243-60. Erratum in: Antiviral Res 1996 Oct;32(2):117.
Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37.
Pari GS, Field AK, Smith JA.
Antimicrob Agents Chemother. 1995 May;39(5):1157-61.
"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.
Field AK, Biron KK.
Clin Microbiol Rev. 1994 Jan;7(1):1-13. Review.
Synthesis and antiviral activity of novel isonucleoside analogs.
Tino JA, Clark JM, Field AK, Jacobs GA, Lis KA, Michalik TL, McGeever-Rubin B, Slusarchyk WA, Spergel SH, Sundeen JE, et al.
J Med Chem. 1993 Apr 30;36(9):1221-9.
The structure and function of the HSV DNA replication proteins: defining novel antiviral targets.
Matthews JT, Terry BJ, Field AK.
Antiviral Res. 1993 Feb;20(2):89-114. Review.
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
Slusarchyk WA, Bisacchi GS, Field AK, Hockstein DR, Jacobs GA, McGeever-Rubin B, Tino JA, Tuomari AV, Yamanaka GA, Young MG, et al.
J Med Chem. 1992 May 15;35(10):1799-806.
Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.
Soike K, Huang JL, Tu JI, Stouffer B, Mitroka JG, Swerdel M, Olsen S, Bonner DP, Tuomari AV, Field AK.
J Infect Dis. 1992 Apr;165(4):732-6.
Selective activity and cellular pharmacology of (1R-1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells.
Yamanaka G, Tuomari AV, Hagen M, McGeever-Rubin B, Terry B, Haffey M, Bisacchi GS, Field AK.
Mol Pharmacol. 1991 Sep;40(3):446-53.
Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.
Braitman A, Swerdel MR, Olsen SJ, Tuomari AV, Lynch JS, Blue B, Michalik T, Field AK, Bonner DP, Clark JM.
Antimicrob Agents Chemother. 1991 Jul;35(7):1464-8.
Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogues.
Bisacchi GS, Braitman A, Cianci CW, Clark JM, Field AK, Hagen ME, Hockstein DR, Malley MF, Mitt T, Slusarchyk WA, et al.
J Med Chem. 1991 Apr;34(4):1415-21.
(+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses.
Field AK, Tuomari AV, McGeever-Rubin B, Terry BJ, Mazina KE, Haffey ML, Hagen ME, Clark JM, Braitman A, Slusarchyk WA, et al.
Antiviral Res. 1990 Jan;13(1):41-52.
Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.
Terry BJ, Mazina KE, Tuomari AV, Haffey ML, Hagen M, Feldman A, Slusarchyk WA, Young MG, Zahler R, Field AK.
Antiviral Res. 1988 Dec 1;10(4-5):235-51.
Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds.
Ashton WT, Meurer LC, Cantone CL, Field AK, Hannah J, Karkas JD, Liou R, Patel GF, Perry HC, Wagner AF, et al.
J Med Chem. 1988 Dec;31(12):2304-15.
Expression of herpes simplex virus type 1 DNA polymerase in Saccharomyces cerevisiae and detection of virus-specific enzyme activity in cell-free lysates.
Haffey ML, Stevens JT, Terry BJ, Dorsky DI, Crumpacker CS, Wietstock SM, Ruyechan WT, Field AK.
J Virol. 1988 Dec;62(12):4493-8.
2'-Nor-2'-deoxyguanosine is an effective therapeutic agent for treatment of experimental herpes keratitis.
Davies ME, Bondi JV, Grabowski L, Schofield TL, Field AK.
Antiviral Res. 1987 Feb;7(2):119-25.
Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections.
Field AK, Davies ME, DeWitt CM, Perry HC, Schofield TL, Karkas JD, Germershausen J, Wagner AF, Cantone CL, MacCoss M, et al.
Antiviral Res. 1986 Oct;6(6):329-41.
Comparison of the modes of antiviral action of 2'-nor-deoxyguanosine and its cyclic phosphate, 2'-nor-cyclic GMP.
Germershausen J, Bostedor R, Liou R, Field AK, Wagner AF, MacCoss M, Tolman RL, Karkas JD.
Antimicrob Agents Chemother. 1986 Jun;29(6):1025-31.
Enzymatic phosphorylation of the antiherpetic agent 9-[(2,3-dihydroxy-1-propoxy)methyl]guanine.
Karkas JD, Ashton WT, Canning LF, Liou R, Germershausen J, Bostedor R, Arison B, Field AK, Tolman RL.
J Med Chem. 1986 May;29(5):842-8.
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade.
Crowell RL, Field AK, Schleif WA, Long WL, Colonno RJ, Mapoles JE, Emini EA.
J Virol. 1986 Feb;57(2):438-45.
Phase I trials of poly(I,C) complexes in advanced cancer.
Krown SE, Kerr D, Stewart WE 2nd, Field AK, Oettgen HF.
J Biol Response Mod. 1985 Dec;4(6):640-9.
Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine.
Ashton WT, Canning LF, Reynolds GF, Tolman RL, Karkas JD, Liou R, Davies ME, DeWitt CM, Perry HC, Field AK.
J Med Chem. 1985 Jul;28(7):926-33.
2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity.
Tolman RL, Field AK, Karkas JD, Wagner AF, Germershausen J, Crumpacker C, Scolnick EM.
Biochem Biophys Res Commun. 1985 May 16;128(3):1329-35.
Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus.
Crumpacker CS, Kowalsky PN, Oliver SA, Schnipper LE, Field AK.
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1556-60.
Efficacy of 2'-nor-2'-deoxyguanosine treatment for orofacial herpes simplex virus type 1 skin infections in mice.
Davies ME, Bondi JV, Field AK.
Antimicrob Agents Chemother. 1984 Feb;25(2):238-41.
Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication.
Tocci MJ, Livelli TJ, Perry HC, Crumpacker CS, Field AK.
Antimicrob Agents Chemother. 1984 Feb;25(2):247-52.
Interferon response to poly IC/poly-L-lysine in normal and lymphocyte-suppressed primates.
DeWitt CM, Field AK.
J Interferon Res. 1984;4(1):1-8.
A comparison of the antiviral agents 2'-nor-2'-deoxyguanosine and acyclovir: uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates.
Germershausen J, Bostedor R, Field AK, Perry H, Liou R, Bull H, Tolman RL, Karkas JD.
Biochem Biophys Res Commun. 1983 Oct 31;116(2):360-7.
9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.
Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DB, Tolman RL.
Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139-43.
Effect of poly I:C/poly-L-lysine (poly ICL) on the development of murine osteogenic sarcoma.
Davies ME, Field AK.
J Interferon Res. 1983;3(1):89-95.
Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG).
Ashton WT, Karkas JD, Field AK, Tolman RL.
Biochem Biophys Res Commun. 1982 Oct 29;108(4):1716-21. No abstract available.
Poly I:C/poly-L-lysine: potent inducer of interferons in primates.
Lampson GP, Field AK, Tytell AA, Hilleman MR.
J Interferon Res. 1981;1(4):539-49.
Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells.
Field AK, Scattergood EM, Hopke CJ, Tytell AA, Hilleman MR.
Antimicrob Agents Chemother. 1980 Dec;18(6):930-2.
Determination of antibodies of double-stranded RNA by enzyme-linked immunosorbent assay (ELISA).
Field AK, Davies ME, Tytell AA.
Proc Soc Exp Biol Med. 1980 Sep;164(4):524-9. No abstract available.
Macrophage dependence of polyriboinosinic acid-polyribocytidylic acid-induced resistance to herpes simplex virus infection in mice.
Martinez D, Lynch RJ, Meeker JB, Field AK.
Infect Immun. 1980 Apr;28(1):147-53.
Histomorphologic assessment of serum thymic factor treatment of NZB/NZW mice.
Mendlowski B, Field AK.
Clin Immunol Immunopathol. 1980 Feb;15(2):144-61. No abstract available.
Resistance of C58 mice to primary systemic herpes simplex virus infection: macrophage dependence and T-cell independence.
Schlabach AJ, Martinez D, Field AK, Tytell AA.
Infect Immun. 1979 Nov;26(2):615-20.
Failure of thymopoietin, ubiquitin and synthetic serum thymic factor to restore immunocompetence in T-cell deficient mice.
Martinez D, Field AK, Schwam H, Tytell AA, Hilleman MR.
Proc Soc Exp Biol Med. 1978 Nov;159(2):195-200. No abstract available.
Safety assessment of poly I:C in NZB/NZW mice (38565).
Mendlowski B, Field AK, Tytell AA, Hilleman MR.
Proc Soc Exp Biol Med. 1975 Feb;148(2):476-83.
The effect of altering the size of poly C on the toxicity and antigenicity of poly I:C.
Lampson GP, Nemes MM, Field AK, Tytell AA, Hilleman MR.
Proc Soc Exp Biol Med. 1972 Dec;141(3):1068-72. No abstract available.
Demonstration of double-stranded ribonucleic acid in concentrates of RNA viruses.
Field AK, Lampson GP, Tytell AA, Hilleman MR.
Proc Soc Exp Biol Med. 1972 Nov;141(2):440-4. No abstract available.
Cellular control of interferon production and release after treatment with poly I:C inducer.
Field AK, Tytell AA, Lampson GP, Hilleman MR.
Proc Soc Exp Biol Med. 1972 Jun;140(2):710-4. No abstract available.
Poly I:C, an inducer of interferon and interference against virus infections.
Field AK, Tytell AA, Piperno E, Lampson GP, Nemes MM, Hilleman MR.
Medicine (Baltimore). 1972 May;51(3):169-74. No abstract available.
Antigenicity of double-stranded ribonucleic acids including poly I:C.
Proc Soc Exp Biol Med. 1972 Apr;139(4):1113-9. No abstract available.
Filters: Manage Filters